Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study by Nogueira, Kátia Camarano et al.
  Universidade de São Paulo
 
2014
 
Left ventricular diastolic function in patients
with type 2 diabetes treated with a dipeptidyl
peptidase-4 inhibitor- a pilot study
 
 
Diabetology & Metabolic Syndrome. 2014 Sep 24;6(1):103
http://dx.doi.org/10.1186/1758-5996-6-103
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Outros departamentos - FM/Outros Artigos e Materiais de Revistas Científicas - FM/Outros
RESEARCH Open Access
Left ventricular diastolic function in patients with
type 2 diabetes treated with a dipeptidyl
peptidase-4 inhibitor- a pilot study
Katia Camarano Nogueira1, Meive Furtado2, Rosa Tsuneshiro Fukui1, Marcia Regina Silva Correia1,
Rosa Ferreira dos Santos1, José Lázaro Andrade2 and Maria Elizabeth Rossi da Silva1*
Abstract
Background: Blood glucose control is fundamental albeit not enough to prevent diabetic macrovascular
complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors are effective in improving metabolic parameters in patients
with type 2 diabetes mellitus (T2DM) but little is known about its cardiovascular effects. We compared the DPP-4
inhibitor sitagliptin with bedtime NPH insulin (NPH) as add-on therapy in patients with T2DM, aiming to ascertain
which drug would have additional cardioprotective effects.
Methods: Thirty-five T2DM patients inadequately controlled with metformin plus glyburide were randomized to
receive sitagliptin (n = 18) or NPH (n = 17) for 24 weeks. Fasting plasma glucose, HbA1c, lipid profile, C-reactive protein,
active glucagon-like peptide (aGLP-1) levels, 24-hour ambulatory blood pressure measurement and comprehensive
2-dimensional echocardiogram were determined before and after treatments.
Results: Both sitagliptin and NPH therapies decreased HbA1c levels after 24 weeks. Fasting plasma glucose and
triglyceride levels decreased in the NPH group whereas only sitagliptin increased aGLP-1 levels. Left ventricular diastolic
dysfunction (LVDD) was detected in 58.6% of twenty-nine patients evaluated. Beneficial effects in LVDD were observed
in 75% and 11% of patients treated with sitagliptin and NPH, respectively (p = 0.015). Neither therapy changed
C-reactive protein or blood pressure.
Conclusions: Sitagliptin and bedtime NPH were similarly effective on glucose control. Improvement in LVDD in T2DM
patients treated with sitagliptin was suggested, probably related to the increase of aGLP-1 levels. Therefore, DPP-4
inhibitor seems to have cardioprotective effects independent of glucose control and may have a role in the prevention
of diabetic cardiomyopathy.
Keywords: Type 2 diabetes mellitus (T2DM), Dypeptidil-peptidase-4 inhibitor, Bedtime NPH insulin, Cardiovascular
function, Glucagon-like peptide 1
Background
Beta-cell dysfunction, insulin resistance and impaired sup-
pression of glucagon are key pathologic defects in type 2
diabetes (T2DM), partially dependent on the reduced
incretin effect [1,2].
In order to achieve appropriate control of diabetes, address
those dysfunctions and prevent vascular complications, the
majority of patients require multiple oral therapies usually
followed by insulin in the long-term. Bedtime NPH insulin
has been well established as third line agent in T2DM treat-
ment [1,3].
Recently, incretin-based therapy with glucagon-like pep-
tide 1 (GLP-1) analogues or dipeptidyl peptidase-4 (DPP-4)
inhibitors, that increase GLP-1 levels, has been proposed as
an alternative to currently available anti-hyperglycemic
agents. GLP-1 acts through GLP-1 receptors expressed not
only in α-, β-, δ-cells of the pancreatic islets, but in a wide
range of tissues including the human heart [2].
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Besides glucose control, DPP-4 inhibitors improve several
cardiovascular risk factors. They may lower blood pressure,
improve renal and endothelial dysfunction and lipid levels
and reduce inflammatory markers, oxidative stress and
platelet aggregation in patients with T2DM. In addition, are
weight neutral and rarely cause hypoglycemia [2,4].
Furthermore, positive effects on the myocardium have
been described in ischemic heart disease. Experimental
evidence from animals and patients (without diabetes)
have revealed inotropic and vasodilator effects of native
GLP-1 and its analogues, increase in myocardial glucose
uptake and reduction in infarct size when given either
prior to injury or at the point of reperfusion [5-7].
The DPP-4 inhibitor sitagliptin in animals and in
nondiabetic subjects have shown similar results [4,8,9],
suggesting a potential cardioprotective effect. DPP-4 in-
hibition may also increase the concentration of many
peptides with potential vasoactive and cardioprotetctive
effects [8].
Only recently, studies have attested that DPP-4 inhibi-
tors are safe in T2D patients and may possibly decrease
the risk of adverse cardiovascular events [10,11].
However, definite relationship between DPP-4 inhibitors
and better cardiovascular outcomes beyond metabolic
control remains to be proven and no study analyzed the
effect of these drugs on myocardial function in patients
with T2DM in a non-ischemic condition. Therefore, we
conducted a comparison of sitagliptin with bedtime NPH
insulin as add-on therapy in T2DM patients inadequately
controlled with metformin plus glyburide, aiming to ascer-
tain whether the DPP-4 inhibitor would have additional
cardioprotective effects.
Methods
Inclusion criteria: 35 Outpatients with T2D (20 F/15 M)
aged 57 ± 7 years (mean ± SD) inadequately controlled
with metformin plus glyburide were randomized to re-
ceive sitagliptin 100 mg once daily (SITA group) or bed-
time NPH insulin- final dose: 11.0 ± 6.7 IU (NPH group)
(Table 1). Exclusion criteria included: severe heart fail-
ure, respiratory failure, uncontrolled hypertension, cor-
onary heart disease, arrhythmias, hepatic and renal
dysfunctions, endocrine and gastrointestinal disorders,
Table 1 Clinical and biochemical characteristics of 35 patients with type 2 diabetes at baseline and after 24-wk of
sitagliptin or bedtime NPH insulin therapy
SITA SITA NPH NPH
Baseline After 24-wk Baseline After 24-wk
Number of patients 18 17
Female/Male 09/09 11/06
Age (years) 55.1 ± 6.7 58.4 ± 6.9
Diabetes duration (years) 10.9 ± 5.8 10.9 ± 7.5
Weight (kg) 69.4 ± 12.0 69.9 ± 11.4 73.1 ± 10.1 74.0 ± 10.4
BMI (kg/m2) 26.5 ± 2.7 26.8 ± 2.6 27.5 ± 2.5 27.8 ± 2.8
Waist-hip ratio 0.97 ± 0.03 0.98 ± 0.05 0.96 ± 0.05 0.95 ± 0.05
sBP vigil (mmHg) 135.4 ± 14.8 130.7 ± 18.9 136.2 ± 11.1 136.1 ± 10.5
dBP vigil (mmHg) 83.1 ± 7.8 81.1 ± 9.6 80.3 ± 8.0 79.2 ± 6.7
sBP sleep (mmHg) 123.1 ± 14.0 122.7 ± 18.8 125.2,3 ± 10.7 129.2 ± 14.9
dBP sleep (mmHg) 71.6 ± 8.5 70.7 ± 9.7 70.3 ± 6.8 71.3 ± 8.7
HbA1c (%) 8.0 ± 0.6 7.3 ± 0.8€ 8.1 ± 0.7 7.3 ± 0.7€
Fasting glucose (mg/dL) 136.5 ± 30.0 125.6 ± 33.4 159.2 ± 38.0 111.6 ± 30.4€
Triglycerides (mg/dL) 139.1 ± 63.5 144.1 ± 66.2 152.6 ± 80.5 130.1 ± 85.3€
Total cholesterol (mg/dL) 171.7 ± 35.1 174.7 ± 33.3 186.8 ± 29.0 185.2 ± 42.0
LDL-cholesterol (mg/dL) 96.6 ± 32.0 101.9 ± 26.7 114.1 ± 21.0§ 121.8 ± 25.6£
HDL-cholesterol (mg/dL) 46.2 ± 9.9 43.4 ± 8.3 42.0 ± 10.2 45.5 ± 11.8
Active GLP-1 (pmol/L) 5.0 ± 2.3 15.3 ± 10.3€ 5.0 ± 2.4 5.6 ± 2.1&
C-reactive protein (mg/L) 2.5 ± 3.1 2.1 ± 2.4 2.7 ± 2.6 2.6 ± 1.6
Data are expressed in means ± SD. BMI, body mass index; GLP-1, glucagon-like peptide 1; sBP, systolic blood pressure; dBP, diastolic blood pressure. SITA,
sitagliptin group; NPH, bedtime insulin NPH group; wk = weeks.
€p < 0.001 for the difference between before and after treatments.
§p = 0.019 for the difference between SITA and NPH groups before treatments.
£p = 0.019 for the difference between SITA and NPH groups after treatments.
&p = 0.001 for the difference between SITA and NPH groups after treatments.
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malignancy, alcohol abuse, use of insulin, beta blockers
or calcium channel antagonists and type 1 DM.
The dosages of metformin (2.4 ± 0.3 x 2.3 ± 0.6 mg/day;
p = 0.46) and of glyburide (17.6 ± 3,1 x 18.1 ± 4.1 mg/day;
p = 0.68) were similar in SITA and NPH groups respect-
ively Also, 77.8% and 64.7% of sitagliptina and NPH
groups were on statin therapy (p = 0.47) and 77.8% and
100% were on IECA or diuretics (p = 0.11), respectively.
All medications were kept constant during the study.
Subjects were followed weekly for drug and dietary
adjustments during the first 30 days and then monthly
throughout the study period. At the time of entry,
complete medical history, physical examination, an-
thropometric and laboratory evaluation were obtained.
The study was approved by the Institutional Review
Board-Comissão de Ética para Análise de Projetos de
Pesquisa - CAPPesq. All participants gave written
informed consent. The following procedures were per-
formed before and after 24 weeks of treatment with
either sitagliptin or bedtime NPH insulin:
Laboratory determinations
Blood samples were collected for fasting plasma glucose
(FPG), HbA1c, lipid profile, C-reactive protein and aGLP-
1 levels. Glucose levels were determined by the glucose
oxidase/peroxidase method (Labtest, Sao Paulo, Brazil)
and glycated hemoglobin (HbA1c) by HPLC (National
Glyco Hemoglobin Standardization Program, USA. Trigly-
ceride levels were measured by the lipase/glycerol kinase
method (Labtest, Sao Paulo, Brazil) and total cholesterol
(total-C) by the cholesterol oxidase/peroxidase method.
HDL-cholesterol (HDL-C) was separated using the phos-
photungstic acid/Mg2+ method and measured by oxidase/
peroxidase method. LDL-cholesterol (LDL-C) was esti-
mated by Friedewald equation. Plasma active GLP-1 levels
(aGLP-1) were measured using the ELISA Kit EGLP-35
(Millipore Corporation, Billerica, MA) on a Spectramax
M5 fluorometer (Molecular Devices, Sunnyvale, CA). The
inter assay and intra assay coefficients of variation were
6% and 4% respectively. C-reactive protein (CRP) was de-
termined by high sensitivity ELISA kits (R&D Systems,
Minneapolis, MN). All determinations were performed in
duplicate.
Cardiovascular evaluation
Blood pressure
Systolic and diastolic blood pressure (BP) values were
assessed by 24-hour ambulatory BP monitoring in all pa-
tients every 20 min from 8.00 am to midnight, and every
30 min from midnight to 8.00 am in the following day.
Echocardiogram
Comprehensive 2-dimensional echocardiogram was per-
formed in 15 patients of SITA group and 14 of NPH
groups. They were positioned in a left lateral position, mon-
itored with electrocardiogram to image acquisition from
longitudinal, transversal, apical four, three and two cham-
bers views, using either a Toshiba Artida (Japan) or a GE
Vivid 7 (EUA) machine with 2,5 MHz transducers. Left
atrium antero-posterior diameter, left ventricle diastolic and
systolic diameters, septal and posterior wall thickness were
measured. Left ventricular volumes were automatically cal-
culated using Simpson’s rule from apical four and two
chambers views. Measurements of mitral inflow included
peak early diastolic velocity (E-wave), late diastolic velocity
(A-wave) and E/A ratio by pulsed Doppler as well as basal
septal early diastolic velocity (e’ wave) by tissue Doppler.
Normal diastolic function was defined as follows: tissue
Doppler septal e’ wave velocity ≥ 8 cm/s, mitral valve E/A
velocities ratio > 1 and < 1.5, E/e’ ratio < 12 and, E wave de-
celeration time (DT) between 150 ms – 240 ms. Left
ventricular diastolic dysfunction (LVDD) was defined as fol-
lows: e’ < 8 and classified as grade I: mild diastolic dysfunc-
tion (e’ < 8 cm/s, E/A < 0.8, E/e’ ≤ 8, DT > 200 ms), grade II:
moderate diastolic dysfunction (e’ < 8 cm/s; E/A 0.8-1.5, E/
e’ 9–12, DT 160 - 200 ms), grade III: severe diastolic
dysfunction (e’ < 8 cm/s; E/A ≥ 2, E/e’ ≥ 13, DT < 160 ms)
[12,13].
The exams were analyzed by two experienced echocar-
diographers, blinded to medications. Six patients
(3 SITA, 3 NPH) did not complete echocardiographic
evaluation and were not included in this analysis.
Statistical analysis
Data were analyzed using SPSS 15.0, SAS 8.0 and Excell
2003 and expressed as mean ± SD. For anthropometric
data, the Student’s t test was used to compare the means.
Differences in clinical characteristics and metabolic
variables among groups were tested with two-way
ANOVA models followed by Tukey’s multiple comparison
tests. Fisher’s exact test was used to assess the association
between the improvement in cardiac function and
therapies. P ≤ 0.05 were considered statistically significant.
Results
At baseline, there were no significant differences between
the two groups with respect to gender, age, duration of dia-
betes, weight, BMI, waist-hip ratio, FPG, HbA1c, CRP,
aGLP-1, total and HDL-cholesterol levels. LDL-cholesterol
was lower in the SITA group (p = 0.019) (Table 1).
Anthropometric and metabolic evaluation
Weight, waist/hip ratio and BMI did not change. Both
treatments resulted in similar decrease in HbA1c values
(p < 0.001). Bedtime NPH insulin therapy also reduced
FPG and triglyceride levels (p < 0.001), but there was no
difference in triglyceride levels between groups after
treatment. CRP, total-C and HDL-C levels did not
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change after 24 weeks of either therapy and remained
similar between groups, whereas final LDL-C levels were
lower in the SITA group in comparison to the NPH
group (p = 0.019), although this difference was already
present at baseline. As expected, fasting plasma aGLP-1
levels increased three times following sitagliptin treat-
ment (p < 0.001), and were higher than those following
NPH treatment (p = 0.001) (Table 1).
Cardiovascular evaluation
Systolic and diastolic ambulatory blood pressure did not
change during periods of vigil or sleep with either
treatment and were similar between groups (p > 0.05)
(Table 1). No significant differences in the echocardio-
graphic evaluation of the diastole were detected between
groups at baseline. Left ventricular diastolic dysfunction
(LVDD) was diagnosed in 53% (8/15) of patients in the
SITA group and in 64% (9/14) of patients in the NPH
group (p = 0.710) (Table 2).
After 24 weeks of treatment, from the 8 patients with
LVDD receiving sitagliptin, 2 patients showed LVDD im-
provement from diastolic dysfunction type II to type I
and 4 patients moved from diastolic dysfunction type I
to normal parameters (75%). On the other hand, from
Table 2 Tissue and conventional Doppler Echocardiographic parameters and grade of left ventricular diastolic
dysfunction by tissue Doppler echocardiograms at baseline and after 24 weeks of treatment with sitagliptin in 15
patients (SITA group) or bedtime NPH insulin in 14 patients (NPH group)
Groups/Patients Baseline After 24-wk
e’ E/e’ E/A LVDD e’ E/e’ E/A LVDD
SITA 1 7.0 10.1 0.9 II 7.0 2.9 0,5 I
2 7.0 5.1 0.6 I 11.0 4.7 0,6 0
3 8.0 9.5 0.7 0 10.0 5.7 0,6 0
4 7.0 7.6 0.9 I 9.9 9.8 1.1 0
5 6.0 9.7 1.8 II 9.1 8.2 2.0 0
6 7.4 7.2 1.1 I 7.0 6.3 0.8 I
7 8.0 8.1 1.0 0 9.0 10.0 1.0 0
8 8.0 4.3 0.6 0 6.8 5.9 0.6 I
9 10.0 6.3 0.8 0 8.0 8.4 1.5 0
10 15.0 6.0 0.8 0 7.0 10.4 0.7 I
11 7.0 11.1 0.9 II 8.0 8.8 1.0 0
12 10.0 5.6 0.7 0 8.0 8.1 0.8 0
13 4.7 12.1 0.8 II 6.1 6.6 0.5 I
14 10.0 6.1 0.9 0 6.4 7.5 0.7 I
15 7.0 10.0 1.1 I 5.8 12.8 0.9 I
NPH 1 7.0 12.0 0.9 II 7.0 13.3 1.2 II
2 6.0 9.8 0.7 II 5.2 12.0 0.6 II
3 7.0 5.7 0.6 I 7.0 4.7 0.5 I
4 6.0 9.8 0.9 II 10.0 9.2 1.7 0
5 4.0 16.5 0.9 II 5.0 12.4 0.7 II
6 8.0 5.3 0.7 0 9.0 5.3 0.7 0
7 10.0 7.3 1.0 0 10.0 6.0 0.9 0
8 18.0 2.8 0.7 0 8.8 6.6 0.7 0
9 6.1 12.1 0.9 I 7.5 10.0 0.8 II
10 10.0 6.8 0.9 0 6.3 11.4 0.8 II
11 4.6 12.0 0.6 II 6.0 10.8 0.8 II
12 7.1 7.7 0.9 I 7.9 10.0 1.3 I
13 5.0 13.6 0.7 I 4,2 16.2 0.6 I
14 8.0 14.2 1.2 0 9.0 10.0 1.0 0
e’ = early diastolic velocity (cm/s); E/e’ =mitral inflow E velocity to tissue Doppler e’ ratio. E/A = early diastolic to late diastolic velocities ratio; LVDD = left
ventricular diastolic dysfunction; 0 = absent LVDD; I = grade I LVDD; II = grade II LVDD; wk = weeks.
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the 9 patients with LVDD receiving bedtime NPH insu-
lin, 1 patient moved from diastolic dysfunction type I to
normal parameters (11%). The difference in improve-
ment rates between the two groups was significant (p =
0.015; OR = 24; CI = 1.74-331. Systolic function remained
normal in all patients. Other parameters analyzed such
as left atrium diameter, LV diastolic and systolic diame-
ters and volumes and septal and posterior wall thickness
were normal in all 29 patients evaluated and did not
change significantly with treatments.
Discussion
The main purpose of our study was to determine which
of two anti-hyperglycemic agents, DPP-4 inhibitor or
bedtime NPH insulin, would better address vascular dys-
function when used as add-on therapy to patients with
T2D inadequately controlled with metformin plus
glyburide. After 24 weeks of therapy, both agents yielded
comparable effects concerning glucose control, as shown
by similar HbA1c levels, evidencing that DPP-4 inhibi-
tors can be used later in the course of the disease, still
retaining effectiveness in patients with long-standing
diabetes.
In addition, an improvement in LVDD was suggested in
patients treated with the DPP-4 inhibitor in comparison
to those treated with bedtime NPH insulin(p = 0.015).
As expected, a high proportion of our patients (59%)
had LVDD [14] that was associated with preserved sys-
tolic function at baseline. It is well established that
LVDD represents the earliest pre-clinical manifestation
of diabetic cardiomyopathy, preceding systolic dysfunc-
tion [15,16]. Early intervention, improving LVDD or pre-
venting its onset, is extremely important because more
than 30% of patients with normal LV systolic function
but decreased diastolic function can progress to congest-
ive heart failure [17].
Tissue Doppler echocardiogram markedly improved the
detection of diastolic dysfunction in asymptomatic patients
[14]. The clinical utility of myocardial velocity measure-
ments for the assessment of diastolic function is widely ac-
cepted and has been documented previously [13].
It has been shown that hyperglycemia leads to LVDD
and its correction can normalize the ventricular function
of patients [18]. Nevertheless, in our study the DPP-4
inhibitor was more effective in improving ventricular
dysfunction than bedtime NPH insulin despite similar
glucose control for both and lower triglyceride level for
NPH. That difference could not be attributed to baseline
characteristics, as both treatment groups had equivalent
prevalence of LVDD. Neither to chances in blood pres-
sure, cholesterol levels and inflammatory status, attested
by no changes on 24-hour ambulatory blood pressure,
cholesterol and C-reactive protein levels. So, the in-
creased aGLP-1 levels due to the DPP-4 inhibition in
patients treated with sitagliptin might have contributed
to the observed improvement in LVDD since beneficial
cardioprotective effects of GLP-1 have been previously
attested in non diabetic subjects [5,6,9].
Experimental data evidenced that sitagliptin may exert
cardioprotective effects by increasing myocardial cAMP
levels and cAMP response element-binding protein (CREB)
phosphorylation [19], a nuclear transcription factor in-
volved in ischemic preconditioning. Alternatively, sitagliptin
may protect the stromal cell-derived factor-1α (SDF-1α), a
substrate of DPP-4 that is overexpressed in response to tis-
sue injury in the ischemic myocardium and is associated
with increased number of circulating progenitor cells [20].
Sitagliptin administration stimulated resident cardiac stem
cells and neovascularization and reduced cardiac remodel-
ing, improving myocardial function and survival after myo-
cardial infarction [21].
Anti-hypertrophic/fibrotic effects on cultured cardiac
cells [8] and reduction of apoptosis and oxidative dam-
age after ischemia/reperfusion, probably by activation of
PI3K/Akt signaling pathway by GLP-1/GLP-1 receptor
[22] collaborated to these results.
By inhibiting CD26 expression on mononuclear cells,
sitagliptin could increase mononuclear cells homing to
the infarct area and improve cardiac recovery and repair
after acute myocardial infarction. The SDF-1alfa/CXCR4
axis plays a major role in cell homing to infarcted myo-
cardium and is negatively regulated by CD226 [23].
Also, patients with heart failure had increased circulating
levels of DPP-4 and there was an inverse correlation be-
tween serum DPP-4 activity and left ventricular ejection
fraction [24].
Further effects include the reduction in renal sodium
reabsorption, interactive hemodynamic effects involving
angiotensin-converting enzyme inhibition and the in-
creased level of substance P, that acts as vasodilator and
is a substrate for DPP-4 [25].
Other factors have to be considered
The possibility that the difference in LVDD after the inter-
vention could be due to a deleterious effect of NPH rather
than a beneficial effect of DPP-4 inhibitor merits atten-
tion. It is known that LVDD is associated with insulin re-
sistance and a deleterious action of insulin on this
parameter and on the development of cardiovascular dis-
ease has been suggested [26]. However, worsening of dia-
stolic function associated with insulin therapy in our study
was unlikely, as it was worsened in only 1 of 14 patients
treated with insulin.
Also, considering the greater association of LVDD with
impaired glucose tolerance but not impaired fasting glu-
cose [27], a “probable” improved glucose control during
wake time with sitagliptin could have influenced our
results. Further, an improvement in insulin resistance,
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another great predictor of LVDD [28], could also have
occurred.
Till now, there is no clear explanation for the increase
in rate of hospitalization for heart failure observed with
saxagliptin, another DPP-4 inhibitor [29]. This result
does not agree with our data and with countless reports
about the benefits of GLP-1 and DPP-4 inhibitors in car-
diac function and merits further study.
No clinically meaningful differences were observed in
the SITA group compared with NPH group with respect
to body weight, BMI and waist-hip ratio, which remained
unchanged in both groups after 24 weeks. Frequent diet-
ary orientation during follow-up visits and the combined
therapy with metformin in all of our patients might have
prevented this. Overall assessment of safety demonstrated
that both drugs were well tolerated in this study, and there
were no significant side effects or severe hypoglycemic
episodes.
Limitations
Left ventricular diastolic function is one of the most dif-
ficult and controversial parameter to be evaluated in
cardiology, considering the many clinical, demographic,
hemodynamic, and echocardiographic variables. No cri-
terion is assessed isolated to diagnose LVDD. For
example, a reduced mitral E/A ratio in the presence of
normal annular tissue Doppler velocities can be seen in
volume-depleted normal subjects, so that an E/A ratio
< 0.8 alone should not be used to infer the presence of
diastolic dysfunction. Furthermore, Grade III LVDD
should not be determinate by a single examination and
requires serial studies after treatment is optimized.
Echocardiographic cut-off values may have slight varia-
tions in different populations. We considered E/A ratio
ranging from 1.8 to 1.9 with deceleration time between
150–240 ms as normal parameters. In the same way E/e’
ratio of 12.1 was considered as type 2 diastolic
dysfunction.
We study a limited number of patients in both groups,
so that further investigation with greater number of pa-
tients should be carried out.
Conclusions
We report a similar effectiveness on glucose control of
the DPP-4 inhibitor sitagliptin and bedtime NPH insulin
as third-line agents in T2DM patients. Furthermore, the
data in this cohort suggested that sitagliptin may have
had cardioprotective effects, seemingly beyond and
independent of glucose control, with positive effects on
left ventricular diastolic function. Therefore, the DPP-4
inhibitor may be a promising drug for the prevention of
diabetic cardiomyopathy.
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